Table 3.
Primary outcomes of patients with pulmonary sarcoidosis depending on the dose of MTX.
| Primary Outcomes | (MTX—10 mg/Week), n = 28 |
(MTX—15 mg/Week), n = 18 |
Chi-Squared Test |
|---|---|---|---|
| Successful completion of treatment |
14 (50.0%) | 15 (83.3%) | 5.225 * p = 0.023 |
| Lack of efficacy | 9 (32.1%) | 1 (5.6%) | 4.552 * p = 0.033 |
| Progression during treatment | 1 (3.6%) | 1 (5.6%) | 0.104 p = 0.748 |
| Serious side effects | 4 (14.3%) | 1 (5.6%) | 2.090 p = 0.149 |
Note: *—the difference in the value of the indicator in the groups is statistically significant with a critical level of significance = 0.05.